CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Titan Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Titan Pharmaceuticals Inc
SUITE 505, 400 OYSTER POINT BLVD
Phone: (415) 244-4990p:415 244-4990 SAN FRANCISCO, CA  94080  United States Ticker: TTNPTTNP
Business Summary
Titan Pharmaceuticals, Inc. is a pharmaceutical company. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus, and Nalmefene Implant, which is for the prevention of relapse in OUD patients following detoxification from opioids Its product development programs are in non-clinical stages of development.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes--Yes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer Weei JyeChay 52 12/2/2024 12/2/2024
Acting Principal Financial Officer, Director BrynnerChiam 47 12/2/2024 10/12/2023
Independent Director AvrahamBen-Tzvi 54 8/15/2022 8/15/2022
3 additional Officers and Directors records available in full report.

Business Names
Business Name
Developmental Therapeutics, Inc.
Ingenex, Inc.
TTNP

General Information
Number of Employees: 4 (As of 3/25/2024)
Outstanding Shares: 914,234 (As of 12/31/2024)
Shareholders: 87
Stock Exchange: NASD
Federal Tax Id: 943171940
Fax Number: (650) 244-4956
Email Address: info@titanpharm.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 19, 2025